Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 24903412)


Identification of an old antibiotic clofoctol as a novel activator of unfolded protein response pathways and an inhibitor of prostate cancer.

Wang M, Shim JS, Li RJ, Dang Y, He Q, Das M, Liu JO.

Br J Pharmacol. 2014 Oct;171(19):4478-89. doi: 10.1111/bph.12800. Epub 2014 Sep 5.


A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.


Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.

Chang HL, Wu YC, Su JH, Yeh YT, Yuan SS.

J Pharmacol Exp Ther. 2008 Jun;325(3):841-9. doi: 10.1124/jpet.107.135442. Epub 2008 Mar 12.


Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo.

Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL, Pang CY.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):315-22. doi: 10.1038/pcan.2013.38. Epub 2013 Sep 17.


4-O-methylhonokiol, a PPARγ agonist, inhibits prostate tumour growth: p21-mediated suppression of NF-κB activity.

Lee NJ, Oh JH, Ban JO, Shim JH, Lee HP, Jung JK, Ahn BW, Yoon DY, Han SB, Ham YW, Hong JT.

Br J Pharmacol. 2013 Mar;168(5):1133-45. doi: 10.1111/j.1476-5381.2012.02235.x.


Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.

Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, Ellsworth E, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, Gomella L, Huszar D, Nevalainen MT.

Clin Cancer Res. 2013 Oct 15;19(20):5658-74. doi: 10.1158/1078-0432.CCR-13-0422. Epub 2013 Aug 13.


Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.

Laurenzana A, Balliu M, Cellai C, Romanelli MN, Paoletti F.

PLoS One. 2013;8(3):e58267. doi: 10.1371/journal.pone.0058267. Epub 2013 Mar 4.


Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.

Chien W, Ding LW, Sun QY, Torres-Fernandez LA, Tan SZ, Xiao J, Lim SL, Garg M, Lee KL, Kitajima S, Takao S, Leong WZ, Sun H, Tokatly I, Poellinger L, Gery S, Koeffler PH.

Oncotarget. 2014 Jul 15;5(13):4881-94.


A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.

Xing ND, Ding ST, Saito R, Nishizawa K, Kobayashi T, Inoue T, Oishi S, Fujii N, Lv JJ, Ogawa O, Nishiyama H.

Asian J Androl. 2011 Mar;13(2):236-41. doi: 10.1038/aja.2010.171. Epub 2011 Feb 7.


Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis.

Yasukochi A, Kawakubo T, Nakamura S, Yamamoto K.

Biol Chem. 2010 Aug;391(8):947-58. doi: 10.1515/BC.2010.087.


Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.

Sankpal UT, Abdelrahim M, Connelly SF, Lee CM, Madero-Visbal R, Colon J, Smith J, Safe S, Maliakal P, Basha R.

Prostate. 2012 Nov;72(15):1648-58. doi: 10.1002/pros.22518. Epub 2012 Apr 2.


A peptidic unconjugated GRP78/BiP ligand modulates the unfolded protein response and induces prostate cancer cell death.

Maddalo D, Neeb A, Jehle K, Schmitz K, Muhle-Goll C, Shatkina L, Walther TV, Bruchmann A, Gopal SM, Wenzel W, Ulrich AS, Cato AC.

PLoS One. 2012;7(10):e45690. doi: 10.1371/journal.pone.0045690. Epub 2012 Oct 1.


ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer.

Jiang J, Loganathan J, Eliaz I, Terry C, Sandusky GE, Sliva D.

Int J Oncol. 2012 May;40(5):1339-44. doi: 10.3892/ijo.2012.1344. Epub 2012 Jan 24.


Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.

Pourpak A, Landowski TH, Dorr RT.

J Pharmacol Exp Ther. 2007 Jun;321(3):1109-17. Epub 2007 Mar 9.


Effects of a human compact anti-ErbB2 antibody on prostate cancer.

Malara AE, Fedele C, Aloj L, Arra C, Laccetti P, D'Alessio G, De Lorenzo C.

Oncol Rep. 2012 Jul;28(1):297-302. doi: 10.3892/or.2012.1760. Epub 2012 Apr 10.


Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling.

Li X, Chen YT, Hu P, Huang WC.

Mol Cancer Ther. 2014 Apr;13(4):855-66. doi: 10.1158/1535-7163.MCT-13-0797. Epub 2014 Feb 3.


Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest.

Chan QK, Lam HM, Ng CF, Lee AY, Chan ES, Ng HK, Ho SM, Lau KM.

Cell Death Differ. 2010 Sep;17(9):1511-23. doi: 10.1038/cdd.2010.20. Epub 2010 Mar 5.


Induction of apoptosis coupled to endoplasmic reticulum stress in human prostate cancer cells by n-butylidenephthalide.

Chiu SC, Chen SP, Huang SY, Wang MJ, Lin SZ, Harn HJ, Pang CY.

PLoS One. 2012;7(3):e33742. doi: 10.1371/journal.pone.0033742. Epub 2012 Mar 28.


Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV.

Mol Cancer Ther. 2014 May;13(5):1067-77. doi: 10.1158/1535-7163.MCT-13-0699. Epub 2014 Mar 27.


A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.

Zins K, Lucas T, Reichl P, Abraham D, Aharinejad S.

PLoS One. 2013 Sep 11;8(9):e74924. doi: 10.1371/journal.pone.0074924. eCollection 2013.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk